drugset / Trial / NCT05223647
Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer
Phase 3
Terminated
239 enrolled
Norwegian University of Science and Technology
Alesund Hospital · collabDrammen sykehus · collabErasmus Medical Center · collabGävle Hospital · collabHaukeland University Hospital · collabHelse Fonna · collabHelse Nord-Trøndelag HF · collabHelse Stavanger HF · collabKarolinska University Hospital · collabLandspitali University Hospital · collabLund University Hospital · collabNordlandssykehuset HF · collabNorth Estonia Medical Centre · collabOslo University Hospital · collabSahlgrenska University Hospital · collabSt. Olavs Hospital · collabSykehuset Innlandet HF · collabUniversity Hospital of North Norway · collabUniversity Hospital, Akershus · collabUniversity Hospital, Linkoeping · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Studies have shown that combining chemotherapy and immune checkpoint inhibitors (ICI) prolongs survival compared with chemotherapy alone in extensive stage small-cell lung cancer (ES SCLC), but the survival benefit is modest. The main aim of this trial is to investigate whether there is a synergistic/additive effect of concurrent thoracic radiotherapy in ES SCLC patients receiving carboplatin/etoposide/durvalumab.
Timeline
- Start
- 2022-01-11
- Primary completion
- 2025-09-04
- Completion
- 2025-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carboplatin | Small molecule | — | — |
| Background | Durvalumab | Monoclonal antibody | — | — |
| Background | Etoposide | Small molecule | — | — |